Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > The cancer phase I is now up on ClinicalTrials.gov

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Jan 13, 2021 10:49am

172 Views

Post# 32284474

RE:The cancer phase I is now up on ClinicalTrials.gov

There will be no testing for Sortilin receptors overexpression in the tumors. I think it is a big weakness of this trial. They will assume Sortilin receptors are overexpressed in every patients and evenly overexpressed. Really not sure about that. I think it will introduce a lot of heterogenicity in the results, on maximum tolerable dose or efficacy.